Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010–2019 – a country with a national tender system for prescription of costly drugs

BACKGROUND: In Norway, an annual tender system for the prescription of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) has been used since 2007. This study aimed to explore annual b/tsDMARDs costs and disease outcomes in Norwegian rheumatoid arthritis (RA) patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Brkic, Alen, Diamantopoulos, Andreas P., Haavardsholm, Espen Andre, Fevang, Bjørg Tilde Svanes, Brekke, Lene Kristin, Loli, Liz, Zettel, Camilla, Rødevand, Erik, Bakland, Gunnstein, Mielnik, Pawel, Haugeberg, Glenn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743354/
https://www.ncbi.nlm.nih.gov/pubmed/35012522
http://dx.doi.org/10.1186/s12913-021-07425-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743354/
https://www.ncbi.nlm.nih.gov/pubmed/35012522
http://dx.doi.org/10.1186/s12913-021-07425-w

Ejemplares similares